Join Growin Stock Community!

Adagene inc.ADAG.US Overview

US StockHealthcare
(No presentation for ADAG)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ADAG AI Insights

ADAG Overall Performance

ADAG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ADAG Recent Performance

-0.68%

Adagene inc.

0.05%

Avg of Sector

-0.31%

S&P500

ADAG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ADAG Key Information

ADAG Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ADAG Profile

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Price of ADAG

ADAG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ADAG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1351.77
PB Ratio
3.69
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-942.99%
Net Margin
-34811.02%
Revenue Growth (YoY)
-74.70%
Profit Growth (YoY)
-598.72%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.91
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1351.77
PB Ratio
3.69
Price-to-FCF
-
Gross Margin
-942.99%
Net Margin
-34811.02%
Revenue Growth (YoY)
-74.70%
Profit Growth (YoY)
-598.72%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is ADAG's latest earnings report released?

    The most recent financial report for Adagene inc. (ADAG) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADAG's short-term business performance and financial health. For the latest updates on ADAG's earnings releases, visit this page regularly.

  • How much debt does ADAG have?

    As of the end of the reporting period, Adagene inc. (ADAG) had total debt of 6.85M, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ADAG have?

    At the end of the period, Adagene inc. (ADAG) held Total Cash and Cash Equivalents of 62.83M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ADAG's EPS continuing to grow?

    According to the past four quarterly reports, Adagene inc. (ADAG)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ADAG?

    Adagene inc. (ADAG)'s Free Cash Flow (FCF) for the period is -11.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 66.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.